Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses

More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by antibodies raised against ancestral SARS-CoV-2 are circulating, highlighting the need to adapt vacci...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Nicole, Schön, Jacob, Hoffmann, Donata, Thran, Moritz, Thess, Andreas, Mueller, Stefan O., Petsch, Benjamin, Rauch, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414064/
https://www.ncbi.nlm.nih.gov/pubmed/36016139
http://dx.doi.org/10.3390/vaccines10081251

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414064/
https://www.ncbi.nlm.nih.gov/pubmed/36016139
http://dx.doi.org/10.3390/vaccines10081251

Ejemplares similares